You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
禮來(LLY.US)在美國偏頭痛藥物專利審判中被判向梯瓦支付1.765億美元
格隆匯 11-10 15:00
格隆匯11月10日丨據市場消息,波士頓聯邦法院的一個陪審團決定,禮來必須向梯瓦製藥國際有限公司支付1.765億美元,此前該公司的偏頭痛藥物Emgality侵犯了梯瓦的三項專利,這些專利與禮來自己的偏頭痛藥物Ajovy有關。這兩種藥物都是通過抗體抑制引起頭痛的肽來治療偏頭痛。禮來公司的一位發言人表示,該公司對判決結果感到失望,但有信心在此案中“最終獲勝”,並表示該決定不會影響其向患者提供Emgality的能力。梯瓦發言人表示,該公司對這一決定感到高興,並將“繼續大力捍衞其知識產權”。根據提交給美國證券交易委員會的公司文件,總部位於印第安納波利斯的禮來公司去年從Emgality的全球銷售中賺取了超過5.77億美元,而總部位於以色列的Teva從Ajovy獲得了3.13億美元。梯瓦表示,預計其兩種品牌藥物Ajovy和治療亨廷頓舞蹈病的藥物Austedo今年的總收入將達到14億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account